No results for ‘’
Syncom Formulations (India) Ltd
₹14.11
(0.28%)
Mon, 25 May 2026, 06:27 pm
Health Technology
Pharmaceuticals: Major
24.5KSyncom Formulations (India) Enterprise Value (EV)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 6.49 | 5.33 | 4.78 | 3.47 | 5.35 | 219.64 | 33.53 | 29.87 | 34.12 | 34.32 | 16.77 | 14.07 | 8.82 | 7.60 | 3.94 | 8.39 | 46.91 | 27.29 | 41.52 | 31.28 |
| Price to book ratio | 1.13 | 0.65 | 0.46 | 0.21 | 0.62 | 0.84 | 1.41 | 1.93 | 4.76 | 3.34 | 1.60 | 1.35 | 0.62 | 0.64 | 0.39 | 1.31 | 4.13 | 2.17 | 3.65 | 4.52 |
| Price to sales ratio | 0.63 | 0.38 | 0.26 | 0.17 | 0.29 | 0.63 | 1.04 | 1.52 | 2.21 | 2 | 0.97 | 0.86 | 0.49 | 0.46 | 0.28 | 1.02 | 4.26 | 2.46 | 4.05 | 3.38 |
| Price to cash flow ratio | 13.09 | 4.49 | 2.93 | 0 | 0 | 0 | 18.16 | 27.93 | 46 | 249.53 | 6.87 | 33.99 | 25.71 | 20.51 | 10.40 | 0 | 61.99 | 74.05 | 0 | 68.51 |
| Enterprise value | 372.75M | 265.56M | 218.8M | 173.25M | 237.35M | 469.43M | 1.19B | 1.68B | 3.22B | 3.34B | 1.74B | 1.59B | 822.6M | 851.11M | 497.8M | 2.33B | 9.44B | 5.6B | 9.92B | 14.61B |
| Enterprise value to EBITDA ratio | 7.53 | 6.07 | 5.95 | 4.44 | 5.29 | 0 | 68.54 | 22.61 | 19.81 | 26.72 | 14.84 | 14.01 | 11.12 | 11.58 | 4.30 | 7.11 | 50.50 | 30.40 | 37.99 | 31.06 |
| Debt to equity ratio | 0.21 | 0.21 | 0.19 | 0.26 | 0.17 | 0.06 | 0.08 | 0.02 | 0.03 | 0.06 | 0.05 | 0.11 | 0.10 | 0.07 | 0.01 | 0.33 | 0.26 | 0.32 | 0.25 | 0.01 |
| Return on equity % | 0 | 12.84 | 9.79 | 6.60 | 9.18 | 0.30 | 4.24 | 6.61 | 10.20 | 9.99 | 9.92 | 9.57 | 7.23 | 8.72 | 10.24 | 17.51 | 9.66 | 8.39 | 9.30 | 15.69 |
Syncom Formulations (India) Ltd Enterprise Value
The Syncom Formulations (India) Ltd Enterprise Value is a key financial metric used by investors to evaluate Syncom Formulations (India) Ltd's valuation, profitability, and overall financial performance. Tracking the Syncom Formulations (India) Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Syncom Formulations (India) Ltd (NSE: SYNCOMF, BSE: 524470) is currently trading at ₹14.11, with a market capitalization of ₹13.34B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Syncom Formulations (India) Ltd Enterprise Value is essential for fundamental analysis.
Syncom Formulations (India) Ltd Enterprise Value Current Value
The current Syncom Formulations (India) Ltd Enterprise Value stands at 14.61B.
The latest Syncom Formulations (India) Ltd Enterprise Value has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Syncom Formulations (India) Ltd Enterprise Value Historical Trend
The Syncom Formulations (India) Ltd Enterprise Value has shown the following historical trend:
- 2024: 14.61B
- 2023: 9.92B
- 2022: 5.6B
- 2021: 9.44B
- 2020: 2.33B
The recent rise in Syncom Formulations (India) Ltd Enterprise Value suggests strengthening valuation trends and improving market sentiment.
What Syncom Formulations (India) Ltd Enterprise Value Indicates for Investors
The Syncom Formulations (India) Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Syncom Formulations (India) Ltd.
Syncom Formulations (India) Ltd Enterprise Value Analysis Summary
The Syncom Formulations (India) Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Syncom Formulations (India) Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Syncom Formulations (India) Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.